HRS-7249 vs Olezarsen

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Severe Hypertriglyceridemia

Shared mechanism: APOC3 · full Severe Hypertriglyceridemia pipeline

HRS-7249

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Severe HypertriglyceridemiaRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07308392 (registry estimate)

No aligned efficacy figure on record for this race.

Olezarsen · Tryngolza

Marketed by Ionis Pharmaceuticals and partners

Approved in Severe Hypertriglyceridemiaantisense oligonucleotide
Reliable signal

NCT05079919 · Phase 3 · completed

This was a randomized, triple-blind, placebo-controlled trial of 617 patients. Both tested doses of olezarsen produced large reductions in triglycerides, the physiological measure that defines this disease, compared with placebo, with strong statistical significance.

Next expected readout: March 2027 · NCT05681351 (registry estimate)

Reported efficacy

Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)

Result source: NCT05552326

Results for Severe Hypertriglyceridemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

HRS-7249: no structured comparison results are available for Severe Hypertriglyceridemia.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olezarsen

Fasting TG -57.05% (n=58) vs -7.77% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-51.67% (n=58) vs -5.59% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-60.92% (n=57) vs -7.77% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-60.39% (n=57) vs -5.59% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 150 mg/dL 79.2% (n=53) vs 11.4% (n=35) placebo @ 26wk50 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
69.8% (n=53) vs 5.7% (n=35) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
84% (n=50) vs 11.4% (n=35) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
82% (n=50) vs 5.7% (n=35) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo C3 -69.63% (n=58) vs -5.47% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-69.09% (n=58) vs -12.4% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-78.72% (n=57) vs -5.47% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-83.78% (n=57) vs -12.4% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Non-HDL-C -22.11% (n=58) vs 3.28% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-20% (n=58) vs -2.55% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-19.79% (n=57) vs 3.28% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-26.57% (n=57) vs -2.55% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
HDL-C 48.02% (n=58) vs 8.38% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
54.2% (n=58) vs 10.53% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
48.01% (n=57) vs 8.38% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
57.43% (n=57) vs 10.53% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Remnant Cholesterol -55.98% (n=58) vs -9.46% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-58.17% (n=58) vs -14.83% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-59.59% (n=57) vs -9.46% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-66.9% (n=57) vs -14.83% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo B -11.42% (n=58) vs 6.82% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-11.67% (n=58) vs 0.68% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-11.67% (n=57) vs 6.82% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-18.53% (n=57) vs 0.68% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo A1 17.37% (n=58) vs 2.84% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
16.37% (n=58) vs 0.81% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
14.91% (n=57) vs 2.84% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
15.46% (n=57) vs 0.81% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Total Cholesterol -6.78% (n=58) vs 2.99% (n=39) placebo @ 26wk50 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-6.08% (n=58) vs -2.15% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-6.48% (n=57) vs 2.99% (n=39) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-10.8% (n=57) vs -2.15% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 500 mg/dL 80% (n=5) vs 75% (n=4) placebo @ 26wk50 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
100% (n=5) vs 75% (n=4) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=7) vs 75% (n=4) placebo @ 26wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=7) vs 75% (n=4) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Acute Pancreatitis 0% (n=58) vs 0% (n=39) placebo @ 52wk50 mg
event count · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=39) placebo @ 52wk*50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Fasting Triglycerides -62.9% @ 25.98wkolezarsen 50 mg
percent change · % of baseline
No placebo or comparator arm
NCT05079919 · Phase 3 · sponsor-reported, not registry data
show 3 more results
-49.2% @ 25.98wkolezarsen 50 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data
-72.2% @ 25.98wkolezarsen 80 mg
NCT05079919 · Phase 3 · sponsor-reported, not registry data
-54.5% @ 25.98wkolezarsen 80 mg
NCT05552326 · Phase 3 · sponsor-reported, not registry data
Available safety results

Olezarsen

Dropout rate
12.1%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
8.8%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
—80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Serious AEs
10.3%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
14%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
50 mg
injection site erythema 13.8% (placebo 0%)
fatigue 10.3% (placebo 2.6%)
urinary tract infection 10.3% (placebo 15.4%)
NCT05355402 · Phase 2 · registry result, not featured evidence
show 1 more result
80 mg
covid-19 7% (placebo 5.1%)
diabetes mellitus 7% (placebo 2.6%)
acute sinusitis 5.3% (placebo 2.6%)
NCT05355402 · Phase 2 · registry result, not featured evidence

Hypertriglyceridemia

Shared mechanism: APOC3 · full Hypertriglyceridemia pipeline

HRS-7249

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in HypertriglyceridemiaRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: June 2027 · NCT07308392 (registry estimate)

No aligned efficacy figure on record for this race.

Olezarsen · Tryngolza

Marketed by Ionis Pharmaceuticals and partners

Phase 3 in Hypertriglyceridemiaantisense oligonucleotide
Reliable signal

NCT05610280 · Phase 3 · completed

Essence-TIMI 73b was a large, randomized, double-blind, placebo-controlled trial in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, or with severe hypertriglyceridemia. The primary outcome was the placebo-adjusted percent change in triglycerides from baseline to 6 months in the moderate-hypertriglyceridemia population (1,349 patients). Triglycerides fell by 58.4 percentage points more than placebo with olezarsen 50 mg and by 60.6 percentage points more with 80 mg (P<0.001 for both), so the primary endpoint was met at both doses. The figures come from the peer-reviewed paper (N Engl J Med 2025).

Next expected readout: March 2027 · NCT05681351 (registry estimate)

Reported efficacy

Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)

Result source: NCT05552326

Results for Hypertriglyceridemia

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

HRS-7249: no structured comparison results are available for Hypertriglyceridemia.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Olezarsen

Fasting TG -60.92% (n=57) vs -7.77% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 7 more results
-60.39% (n=57) vs -5.59% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-57.05% (n=58) vs -7.77% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-51.67% (n=58) vs -5.59% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-60% (n=22) vs 6% (n=24) placebo50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
-56% (n=23) vs 6% (n=24) placebo15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
-23% (n=22) vs 6% (n=24) placebo10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
-60% (n=23) vs 6% (n=24) placebo10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 150 mg/dL 84% (n=50) vs 11.4% (n=35) placebo @ 26wk80 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 7 more results
82% (n=50) vs 5.7% (n=35) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
79.2% (n=53) vs 11.4% (n=35) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
69.8% (n=53) vs 5.7% (n=35) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
90.9% (n=22) vs 4.2% (n=24) placebo50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
65.2% (n=23) vs 4.2% (n=24) placebo15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
13.6% (n=22) vs 4.2% (n=24) placebo10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
73.9% (n=23) vs 4.2% (n=24) placebo10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
Apo C3 -78.72% (n=57) vs -5.47% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-83.78% (n=57) vs -12.4% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-69.63% (n=58) vs -5.47% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-69.09% (n=58) vs -12.4% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Non-HDL-C -19.79% (n=57) vs 3.28% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-26.57% (n=57) vs -2.55% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-22.11% (n=58) vs 3.28% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-20% (n=58) vs -2.55% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
HDL-C 48.01% (n=57) vs 8.38% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
57.43% (n=57) vs 10.53% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
48.02% (n=58) vs 8.38% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
54.2% (n=58) vs 10.53% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Remnant Cholesterol -59.59% (n=57) vs -9.46% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-66.9% (n=57) vs -14.83% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-55.98% (n=58) vs -9.46% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-58.17% (n=58) vs -14.83% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo B -11.67% (n=57) vs 6.82% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-18.53% (n=57) vs 0.68% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-11.42% (n=58) vs 6.82% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-11.67% (n=58) vs 0.68% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Apo A1 14.91% (n=57) vs 2.84% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
15.46% (n=57) vs 0.81% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
17.37% (n=58) vs 2.84% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
16.37% (n=58) vs 0.81% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Total Cholesterol -6.48% (n=57) vs 2.99% (n=39) placebo @ 26wk80 mg
percent change · % of baseline
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
-10.8% (n=57) vs -2.15% (n=39) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-6.78% (n=58) vs 2.99% (n=39) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
-6.08% (n=58) vs -2.15% (n=39) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Fasting TG Less Than 500 mg/dL 100% (n=7) vs 75% (n=4) placebo @ 26wk80 mg
responder rate · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence
show 3 more results
100% (n=7) vs 75% (n=4) placebo @ 52wk80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
80% (n=5) vs 75% (n=4) placebo @ 26wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
100% (n=5) vs 75% (n=4) placebo @ 52wk50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
Acute Pancreatitis 0% (n=57) vs 0% (n=39) placebo @ 52wk80 mg
event count · % of participants
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 3 more results
0% (n=57) vs 0% (n=39) placebo @ 52wk*80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=58) vs 0% (n=39) placebo @ 52wk*50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=58) vs 0% (n=39) placebo @ 52wk*50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence · converted to % from 0 Participants as posted
Fasting TG Less Than 100 mg/dL 45.5% (n=22) vs 0% (n=24) placebo50 mg Q4W
responder rate · % of participants
NCT03385239 · Phase 2 · registry result, not featured evidence
show 3 more results
30.4% (n=23) vs 0% (n=24) placebo15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
0% (n=22) vs 0% (n=24) placebo10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
26.1% (n=23) vs 0% (n=24) placebo10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence

+ 1 further endpoint in the CSV export.

Available safety results

Olezarsen

Dropout rate
8.8%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
12.1%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
0%50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
13%15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
13.6%10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
17.4%10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
—50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
0%50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
4.3%15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
0%10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
0%10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
Serious AEs
14%80 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
10.3%50 mg
NCT05355402 · Phase 2 · registry result, not featured evidence
13.6%50 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
17.4%15 mg Q2W
NCT03385239 · Phase 2 · registry result, not featured evidence
13.6%10 mg Q4W
NCT03385239 · Phase 2 · registry result, not featured evidence
4.3%10 mg QW
NCT03385239 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
80 mg
covid-19 7% (placebo 5.1%)
diabetes mellitus 7% (placebo 2.6%)
acute sinusitis 5.3% (placebo 2.6%)
NCT05355402 · Phase 2 · registry result, not featured evidence
show 5 more results
50 mg
injection site erythema 13.8% (placebo 0%)
fatigue 10.3% (placebo 2.6%)
urinary tract infection 10.3% (placebo 15.4%)
NCT05355402 · Phase 2 · registry result, not featured evidence
50 mg Q4W
injection site erythema 18.2% (placebo 0%)
nasopharyngitis 18.2% (placebo 12.5%)
nausea 18.2% (placebo 4.2%)
NCT03385239 · Phase 2 · registry result, not featured evidence
15 mg Q2W
nasopharyngitis 17.4% (placebo 12.5%)
arthralgia 13% (placebo 0%)
dizziness 13% (placebo 0%)
NCT03385239 · Phase 2 · registry result, not featured evidence
10 mg Q4W
anaemia 13.6% (placebo 0%)
arthralgia 13.6% (placebo 0%)
back pain 13.6% (placebo 4.2%)
NCT03385239 · Phase 2 · registry result, not featured evidence
10 mg QW
injection site erythema 21.7% (placebo 0%)
nasopharyngitis 21.7% (placebo 12.5%)
upper respiratory tract infection 17.4% (placebo 12.5%)
NCT03385239 · Phase 2 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HRS-7249's landscape · Olezarsen's landscape